Welcome to: Rimonabant Information Source (does rimonabant work?)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

A panel of experts meets Wednesday to help the Food and Drug Administration to decide whether a highly anticipated experimental diet drug for obesity should be approved for sale in the United States. An FDA advisory committee, the data on rimonabant, a drug that decreases people driving to eat. Of particular concern: potential side effects including depression and anxiety. The agency is often associated with the Committee recommendation. A decision is expected by the end of July. If approved, rimonabant would be sold as the prescription medication Zimulti Sanofi-Aventis. The drug is already sold in Europe. Most Popular 3 Questions No Job Seeker Ever Wants To Be Asked? Business Plan Sample 10 jobs that pay $ 30 An Hour 13 Job Interview errors that market-based government through innovation: How public sector leaders are improving collaboration and listening to the public only a few other prescription diet drugs on the market in the United States, including one that keeps some dietary fat is absorbed by the body and another who works in the brains chemistry to enhance fullness.

Rimonabant Pricelist

Please wait while we load the price list
What is Rimonabant used for? Clinical trials have shown that heavy smokers, after being on a regular supplement of Rimonabant, have stopped smoking altogether. Smokers usually do not stop smoking for fear of weight-gain, which can be highly discouraging. However since Rimonabant works on the overeating and smoking factors simultaneously such problems wouldn't arise. Does Rimonabant also aid smoking cessation? • Rimonabant acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1 • Rimonabant switches off the same brain circuits that make people hungry when they smoke cannabis • CB1 receptor blockade with Rimonabant acts to decrease the over activity of the endocannabinoid system (EC system) 2, 3.

In RIO-Europe, 20 mg/day of rimonabant resulted in a mean 7. 2-kg weight loss among those who completed 2 years of treatment, compared with a mean 2. 5-kg loss in those on placebo. In an intent-to-treat analysis, the mean weight loss was 5. 5 kg in the rimonabant arm and 1. 2 kg with placebo. At baseline, more than 42% of study participants met National Cholesterol Education Program criteria for metabolic syndrome. After 2 years on rimonabant 20 mg/day, the prevalence of metabolic syndrome fell by 57%, compared with a 34% drop with placebo. Mean waist circumference--a measure of intraabdominal obesity--was reduced by 7. 5 cm after 2 years on rimonabant, from a baseline of 110 cm, and by 3. 4 cm in the placebo group. More than 32% of patients who completed 2 years of rimonabant treatment lost at least 10% of their baseline body weight--a medically meaningful threshold--as compared with 11% on placebo.